You searched for "intracameral"

515 results found

Optic nerve swelling – your survival guide (part 2)

In this second article we will discuss bilateral optic nerve swelling, its aetiology, various investigations and possible treatments. We will also discuss various protocols used in the management of suspected optic nerve swelling cases. (Part one of this topic available...

Orbital Schwannomas

This is a large case series of orbital Schwannomas managed at a single centre over a 26-year period. Twenty Schwannomas are reported, all but one of which was managed surgically. The tumours were all benign, had an insidious onset and...

Insects, swelling and sight loss: a case of orbital inflammatory syndrome

Despite being the most common cause of painful orbital mass in adults and the third most common orbital disease, orbital inflammatory syndrome still proves to be a difficult ocular condition to diagnose, treat, and manage. A 41-year-old lady presented to...

Effect of minor trauma in eyes with previously undiagnosed angioid streaks

Angioid streaks (AS) may be associated with pseudoxanthoma elasticum (PXE), Paget’s disease, haemoglobulinopathies, Ehlers-Danlos Syndrome or abetalipoproteinaemia. Histopathology showed retinal pigment epithelium (RPE) and choriocapillaris loss, elastic fibre degeneration, calcium deposition, active choroidal neovascular membrane (CNVM) and vascular endothelial growth...

Patients blinded by stem cells! How safe are they really?

Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

G-CSF intravitreal injections for NAION: a pilot study

In rodent models with anterior ischemic optic neuropathy (AION), granulocyte colony-stimulating factor (G-CSF) confers a neuroprotective effect on retinal ganglion cells (RGCs) via anti-apoptotic and anti-inflammatory processes. This prospective study investigated the efficacy of intravitreal injection of G-CSF for the...

Troubleshooting in LASIK

Contemporary laser in situ keratomileusis (LASIK) is safe and effective. It remains the dominant intervention in routine refractive surgery for a good reason: predictable results, rapid visual recovery, and relatively simple strategies for revision treatment. Over 95% of patients are...

Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections

This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...

Evaluation of fluocinolone acetonide in the management of BRC

This is a single-centre, retrospective, intervention study of 15 eyes of birdshot retinochoroiditis (BRC) patients who received Iluvein, with a mean follow-up period of 31 months. Five eyes had previously received dexamethasone intravitreal implant 0.7mg (Ozurdex). Fluorescein angiography (FA) showed...

Practice patterns in managing exogenous endophthalmitis

The authors of this study conducted a global survey of medical institutions regarding management of exogenous endophthalmitis to assess current practice patterns for this sight-threatening emergency. Thirty-six (of 42 institutions) responded and were included in the analysis. Results were as...

ROP ocular outcomes after Bevacizumab treatment

The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...